<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D3EB34F1-7CAE-41B1-A951-98FA4BE48D2E"><gtr:id>D3EB34F1-7CAE-41B1-A951-98FA4BE48D2E</gtr:id><gtr:name>Janssen Biotech, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/154E784F-8FF4-4E34-BC5B-F762118ABF4F"><gtr:id>154E784F-8FF4-4E34-BC5B-F762118ABF4F</gtr:id><gtr:name>Kings College London (KCL), MRC Centre for Transplantation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D3EB34F1-7CAE-41B1-A951-98FA4BE48D2E"><gtr:id>D3EB34F1-7CAE-41B1-A951-98FA4BE48D2E</gtr:id><gtr:name>Janssen Biotech, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/154E784F-8FF4-4E34-BC5B-F762118ABF4F"><gtr:id>154E784F-8FF4-4E34-BC5B-F762118ABF4F</gtr:id><gtr:name>Kings College London (KCL), MRC Centre for Transplantation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/042218C3-88CB-4880-BD2B-57A9941D2019"><gtr:id>042218C3-88CB-4880-BD2B-57A9941D2019</gtr:id><gtr:firstName>Randolph</gtr:firstName><gtr:surname>Noelle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802651"><gtr:id>9AE2DA32-8A15-47A8-9323-9FFB3058ABC5</gtr:id><gtr:title>Strategic Appointment of Professor Randolph Noelle</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802651</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2012-11-15</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-11-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1199997</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>Treg adoptive therapy</gtr:description><gtr:id>4B65675C-8377-4CDA-BA2F-CD9A01570CD0</gtr:id><gtr:impact>Submission of a number of grant applications</gtr:impact><gtr:partnerContribution>High level interactions with the Lombardi/Lechler LabInteractions with Lord Lab</gtr:partnerContribution><gtr:piContribution>Technology and knowledge concerning retinoic acid receptors</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL), MRC Centre for Transplantation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Transplantation Immunology and Mucosal Biology</gtr:department><gtr:description>Retinoic acid and regulatory T cell function</gtr:description><gtr:id>15FAC6AB-6B5E-4EB7-981F-EBC0547C566C</gtr:id><gtr:impact>None</gtr:impact><gtr:partnerContribution>Dr Lombardi has the expertise to study regulatory T cell functions in transplantation</gtr:partnerContribution><gtr:piContribution>We have provided unique genetically engineered mouse models to study regulatory T cell function</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>Treg adoptive therapy</gtr:description><gtr:id>CAB9A689-1CCF-4655-B33F-F33A4322922D</gtr:id><gtr:impact>Submission of a number of grant applications</gtr:impact><gtr:partnerContribution>High level interactions with the Lombardi/Lechler LabInteractions with Lord Lab</gtr:partnerContribution><gtr:piContribution>Technology and knowledge concerning retinoic acid receptors</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Biotech, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Oncology Discovery</gtr:department><gtr:description>Development of VISTA therapeutics</gtr:description><gtr:id>E12F1D9B-19F0-4228-9016-AF6E7E72D5A1</gtr:id><gtr:impact>Developing fully human anti-human mabs for clinical development.</gtr:impact><gtr:partnerContribution>Expertise is development of fully human anti-human mabs</gtr:partnerContribution><gtr:piContribution>Systems to study the activity of new therapeutic antibodies specific to VISTA</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL), MRC Centre for Transplantation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Transplantation Immunology and Mucosal Biology</gtr:department><gtr:description>VISTA in inflammatory bowel disease</gtr:description><gtr:id>D6964C3F-9A52-4997-8D28-47940FA9E28D</gtr:id><gtr:impact>None</gtr:impact><gtr:partnerContribution>Test VISTA-Ig molecules in murine models of inflammatory bowel disease</gtr:partnerContribution><gtr:piContribution>Produce VISTA-Ig molecules for therapy</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Ultrastructural Imaging</gtr:department><gtr:description>VISTA Structure</gtr:description><gtr:id>12E71B30-5814-45CD-89CD-41A9E391D8B5</gtr:id><gtr:impact>Involvement of pharmaceutical interest in VISTA structure.</gtr:impact><gtr:partnerContribution>Analysis of structure of VISTA recombinant molecules</gtr:partnerContribution><gtr:piContribution>Provided VISTA proteins for structural studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>VISTA</gtr:description><gtr:id>D44FF4F2-DB83-40AC-B827-C0F44063A194</gtr:id><gtr:impact>None as of yet</gtr:impact><gtr:partnerContribution>Provided expertise in protein biochemistry</gtr:partnerContribution><gtr:piContribution>Production of VISTA engineered proteins for future immunotherapy</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL), MRC Centre for Transplantation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Transplantation Immunology and Mucosal Biology</gtr:department><gtr:description>VISTA in kidney disease</gtr:description><gtr:id>D7284E2D-EA82-4621-B03F-4C2F71F9C2C7</gtr:id><gtr:impact>none</gtr:impact><gtr:partnerContribution>Partner is an expert in murine models of kidney disease and tests the impact of anti-VISTA and VISTA-Ig</gtr:partnerContribution><gtr:piContribution>We produce anti-VISTA mabs and VISTA-Ig for testing in kidney disease models.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Principal Research Fellowship - New (The cellular and molecular basis for the impact of vitamin A on immunity)</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>D5BBF8BC-4341-4FA5-9F61-D574B629F4B2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:department><gtr:description>Cognate Interaction of B lymphocytes</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>R37 AI26296</gtr:fundingRef><gtr:id>59D84980-F65D-4D83-9C2E-B0868FF457AF</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2003-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>D49744A7-8A31-4BCF-94E7-1DBBBDBBF8DB</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates .alpha.CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon .alpha.CD3/.alpha.GITR stimulation. This protein has been designated T.sup.reg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed</gtr:description><gtr:id>74146205-1324-4265-9B37-D29A0BD5455B</gtr:id><gtr:impact>na</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2012195894</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection.</gtr:description><gtr:id>E47B3F71-5F3D-44B3-974E-A173125A9FA9</gtr:id><gtr:impact>The present specification provides compounds, compositions and methods using such compounds and compositions to treat an autoimmune disorder, inflammation and/or a transplant rejection.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2012125749</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.</gtr:description><gtr:id>00D2BFB9-91E5-48F2-8902-3E723A71C5AF</gtr:id><gtr:impact>na</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2011280903</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>IMMUNOSTIMULATORY COMBINATIONS</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Describes the use of antibodies to a novel protein (PD-L3) to control T cell responses.</gtr:description><gtr:id>F97AAB75-854E-40F0-B248-E8E3F4C33CD1</gtr:id><gtr:impact>Targetting this molecule (PD-L3, VISTA) will allow enhanced immune responses to tumors and enhance tumor rejection</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US8501915</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antibodies to PD-L3 (VISTA)</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Describes methods to produce regulatory T cells in vitro</gtr:description><gtr:id>09ED8DA2-48D8-4886-B697-5B440FCFC074</gtr:id><gtr:impact>The methods described will be useful for producing stable adaptive regulatory T cells for therapy in humans with autoimmune disease and for graft rejection</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US8415154</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Adaptive T regulatory cells</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We have recently (Sept 2012) closed a $150 Million dollar milestone agreement with JNJ for the development of anti-VISTA mabs for the treatment of cancer.</gtr:description><gtr:id>ED2028B9-B540-4079-B339-AE01588603F0</gtr:id><gtr:impact>It is anticipated that anti-VISTA will have profound impact on the development of anti-tumor immunity in man.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Anti-VISTA Therapeutics in Oncology Licensing to JNJ Pharmaceuticals</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>VISTA-Ig represents a new class of immunosuppressive drugs. We are in the final phases of term sheet agreements with large pharma for the development of this class of drugs.</gtr:description><gtr:id>A1E7E134-3CB1-454A-80A0-7840B810CF2B</gtr:id><gtr:impact>We are currently in preclinical testing of VISTA-Ig in a variety of murine autoimmune models. Large pharma has expressed interest and we are in the final phases of licensing this new drug to pharma.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>VISTA-Ig agonists for the treatment of autoimmunity (In final negotiation of licensing to Pharma)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have produced mice in which retinoid acid synthesis can be manipulated.</gtr:description><gtr:id>7BDA99DE-F622-464D-8E1B-47E6050EE7CA</gtr:id><gtr:impact>This mouse strain will uniquely be able to define lineages of cells that must make retinoid acid to support immunity</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Retinoic Acid engineered mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Produced antibodies to both mouse and human VISTA and produced KO mice as well as conditional KO mice.</gtr:description><gtr:id>05E8FCC6-2261-4BFC-BFA0-7459ACD4E72C</gtr:id><gtr:impact>Allows investigation of a newly described molecule that we discovered in our lab in 2011.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>VISTA antibodies and reagents</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>ImmuNext</gtr:companyName><gtr:description>In 2006 I co-founded ImmuNext and am currently CSO. The company is involved in developing biotherapeutics for autoimmunity and cancer.</gtr:description><gtr:id>EFD3A154-107A-4DF6-97D0-EDAB1B17184B</gtr:id><gtr:impact>Licensing to JNJ a new antibody based therapeutic for cancer. Licensing &amp;gt;$150 M in milestones plus royalties. Also in the process of licensing VISTA-Ig as a novel therapeutic for the treatment of autoimmune disease.</gtr:impact><gtr:url>http://www.immunext.com</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77310EDA-1BA4-4562-9014-8A662CD35BD8"><gtr:id>77310EDA-1BA4-4562-9014-8A662CD35BD8</gtr:id><gtr:title>Retinoic acid: a key player in immunity.</gtr:title><gtr:parentPublicationTitle>BioFactors (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45fff384471232c7ff0cb2ee3bd4f169"><gtr:id>45fff384471232c7ff0cb2ee3bd4f169</gtr:id><gtr:otherNames>Pino-Lagos K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0951-6433</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5F9A1A8-B30C-4083-8B8D-C865B3F0905E"><gtr:id>C5F9A1A8-B30C-4083-8B8D-C865B3F0905E</gtr:id><gtr:title>Mast cell protease 6 is required for allograft tolerance.</gtr:title><gtr:parentPublicationTitle>Transplantation proceedings</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7eba7d9d037e00a62a92761ccf2751b2"><gtr:id>7eba7d9d037e00a62a92761ccf2751b2</gtr:id><gtr:otherNames>de Vries VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/13C9A0B1-0BE9-48C3-8EA9-1DE28565D1E9"><gtr:id>13C9A0B1-0BE9-48C3-8EA9-1DE28565D1E9</gtr:id><gtr:title>Autoimmune diseases have been the focus of intense research efforts.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7011a4438f4652587aa2a06a5d5bb90c"><gtr:id>7011a4438f4652587aa2a06a5d5bb90c</gtr:id><gtr:otherNames>Wucherpfennig KW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EBC9BC94-E248-41B6-B107-011DB6F6E3B5"><gtr:id>EBC9BC94-E248-41B6-B107-011DB6F6E3B5</gtr:id><gtr:title>A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2585257962f19c804855e5920219ec8c"><gtr:id>2585257962f19c804855e5920219ec8c</gtr:id><gtr:otherNames>Guo Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1ADEE46-9B7E-4D27-81F4-6F9E1DE639C1"><gtr:id>E1ADEE46-9B7E-4D27-81F4-6F9E1DE639C1</gtr:id><gtr:title>Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b42addebc78047fa3724c2aee5ea398f"><gtr:id>b42addebc78047fa3724c2aee5ea398f</gtr:id><gtr:otherNames>Gunturu KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2CB83FC9-20D4-4115-BF2A-61DBB406E45F"><gtr:id>2CB83FC9-20D4-4115-BF2A-61DBB406E45F</gtr:id><gtr:title>Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87b677d4d98cbb244cc46a69c9bbb7d6"><gtr:id>87b677d4d98cbb244cc46a69c9bbb7d6</gtr:id><gtr:otherNames>O'Connor RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1EF37451-D08D-490F-B575-B20E2BE16E31"><gtr:id>1EF37451-D08D-490F-B575-B20E2BE16E31</gtr:id><gtr:title>The roles of mast cells in anticancer immunity.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bd371f716a998e1250a69f8f10acb00b"><gtr:id>bd371f716a998e1250a69f8f10acb00b</gtr:id><gtr:otherNames>Dalton DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/419A732F-AA29-4C8E-B900-3627405FA101"><gtr:id>419A732F-AA29-4C8E-B900-3627405FA101</gtr:id><gtr:title>Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d862df29bfe1335deda4f8b201d7e620"><gtr:id>d862df29bfe1335deda4f8b201d7e620</gtr:id><gtr:otherNames>Allie SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A73C665B-0037-4E59-BCCE-D3B01100025F"><gtr:id>A73C665B-0037-4E59-BCCE-D3B01100025F</gtr:id><gtr:title>VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D63D19E4-C5CD-406F-9928-74DC4434947E"><gtr:id>D63D19E4-C5CD-406F-9928-74DC4434947E</gtr:id><gtr:title>Cellular sources and immune functions of interleukin-9.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ff3cd150aae0be84ceaf23c21444424"><gtr:id>5ff3cd150aae0be84ceaf23c21444424</gtr:id><gtr:otherNames>Noelle RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FD24347-ECA8-4079-A8C6-D9721DA7D8F0"><gtr:id>7FD24347-ECA8-4079-A8C6-D9721DA7D8F0</gtr:id><gtr:title>Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0644ad0dc90cfaccfa5695a7f640d47"><gtr:id>a0644ad0dc90cfaccfa5695a7f640d47</gtr:id><gtr:otherNames>Aoyama K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09550C26-7433-4CDF-A6BA-2142DB50AFC5"><gtr:id>09550C26-7433-4CDF-A6BA-2142DB50AFC5</gtr:id><gtr:title>B7 family checkpoint regulators in immune regulation and disease.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eec8150503ee523e784a00bba8222bc5"><gtr:id>eec8150503ee523e784a00bba8222bc5</gtr:id><gtr:otherNames>Ceeraz S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2FF65B4-4599-4FD6-B4C6-6413C669D47A"><gtr:id>C2FF65B4-4599-4FD6-B4C6-6413C669D47A</gtr:id><gtr:title>Mast cell mediators in tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7eba7d9d037e00a62a92761ccf2751b2"><gtr:id>7eba7d9d037e00a62a92761ccf2751b2</gtr:id><gtr:otherNames>de Vries VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD395342-6C32-4A37-9FA2-4494631F60F2"><gtr:id>BD395342-6C32-4A37-9FA2-4494631F60F2</gtr:id><gtr:title>Mast cells impair the development of protective anti-tumor immunity.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0dc2f8e787f289f6257822ab6d922e46"><gtr:id>0dc2f8e787f289f6257822ab6d922e46</gtr:id><gtr:otherNames>Wasiuk A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D016692E-5888-4179-BD71-4673DFE03248"><gtr:id>D016692E-5888-4179-BD71-4673DFE03248</gtr:id><gtr:title>A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/45fff384471232c7ff0cb2ee3bd4f169"><gtr:id>45fff384471232c7ff0cb2ee3bd4f169</gtr:id><gtr:otherNames>Pino-Lagos K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C943E52-AC08-4B52-9579-9BB759BB9743"><gtr:id>4C943E52-AC08-4B52-9579-9BB759BB9743</gtr:id><gtr:title>Interleukin-9 and T cell subsets.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c92bb4fda04a473625d592b998f8eff3"><gtr:id>c92bb4fda04a473625d592b998f8eff3</gtr:id><gtr:otherNames>Nowak EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4344C9DB-EF79-48E4-8CC0-BB071A495557"><gtr:id>4344C9DB-EF79-48E4-8CC0-BB071A495557</gtr:id><gtr:title>CCR6-dependent positioning of memory B cells is essential for their ability to mount a recall response to antigen.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/683d85c4205a3be0e17b5d658643e8a1"><gtr:id>683d85c4205a3be0e17b5d658643e8a1</gtr:id><gtr:otherNames>Elgueta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFE5FAAB-70C2-4E6A-B5F3-6478BB981FD8"><gtr:id>FFE5FAAB-70C2-4E6A-B5F3-6478BB981FD8</gtr:id><gtr:title>Mast cells condition dendritic cells to mediate allograft tolerance.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7eba7d9d037e00a62a92761ccf2751b2"><gtr:id>7eba7d9d037e00a62a92761ccf2751b2</gtr:id><gtr:otherNames>de Vries VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2CFCF098-DFC6-456D-8B7E-9A462882D123"><gtr:id>2CFCF098-DFC6-456D-8B7E-9A462882D123</gtr:id><gtr:title>The immortality of humoral immunity.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/683d85c4205a3be0e17b5d658643e8a1"><gtr:id>683d85c4205a3be0e17b5d658643e8a1</gtr:id><gtr:otherNames>Elgueta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7AA5CFDA-93B9-4F25-ACCB-7E11AF180674"><gtr:id>7AA5CFDA-93B9-4F25-ACCB-7E11AF180674</gtr:id><gtr:title>Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aec99f4d429d0257c3bd2456730eeed5"><gtr:id>aec99f4d429d0257c3bd2456730eeed5</gtr:id><gtr:otherNames>Benson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD82B920-580B-41DC-A935-7ABEFFEABD30"><gtr:id>FD82B920-580B-41DC-A935-7ABEFFEABD30</gtr:id><gtr:title>Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f91e00c92a00a090f7c648614fdd4c46"><gtr:id>f91e00c92a00a090f7c648614fdd4c46</gtr:id><gtr:otherNames>Lievens D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CCA3DA2D-5A66-4834-8582-4DB7B5654A2D"><gtr:id>CCA3DA2D-5A66-4834-8582-4DB7B5654A2D</gtr:id><gtr:title>The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d4ac4ae1006ba152d55ab78a525f0eb0"><gtr:id>d4ac4ae1006ba152d55ab78a525f0eb0</gtr:id><gtr:otherNames>Stan RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/95A57712-9AD3-44D3-8918-2AE536DEC126"><gtr:id>95A57712-9AD3-44D3-8918-2AE536DEC126</gtr:id><gtr:title>Interleukin-9 as a T helper type 17 cytokine.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c92bb4fda04a473625d592b998f8eff3"><gtr:id>c92bb4fda04a473625d592b998f8eff3</gtr:id><gtr:otherNames>Nowak EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B05E85C-C58D-41BC-BF70-CC56E34F3111"><gtr:id>4B05E85C-C58D-41BC-BF70-CC56E34F3111</gtr:id><gtr:title>Tryptophan hydroxylase-1 regulates immune tolerance and inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c92bb4fda04a473625d592b998f8eff3"><gtr:id>c92bb4fda04a473625d592b998f8eff3</gtr:id><gtr:otherNames>Nowak EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C026850-47F2-40CE-9895-C36385037A5E"><gtr:id>5C026850-47F2-40CE-9895-C36385037A5E</gtr:id><gtr:title>Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb043edd31102bd19d80616ef0459c05"><gtr:id>cb043edd31102bd19d80616ef0459c05</gtr:id><gtr:otherNames>Lutgens E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802651</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>